← Leaderboards
Nikki Gillum Posnack
George Washington University
$8,035,251
Attributed
$8,035,251
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,035,251 · 5
By mechanism
R01$6,938,598 · 2
R00$739,807 · 1
K99$209,926 · 1
F32$146,920 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Adverse Effects”
- James Dennis Neaton · Northwestern University$203,539,316
- John M Lachin · George Washington University$139,991,329
- Elizabeth A Thom · George Washington University$126,101,581
- David M Nathan · Massachusetts Institute Of Technology$120,651,895
- Constance Ann Benson · University Of California, San Diego$114,806,215
- Wafaa M. El-Sadr · Columbia University Health Sciences$102,102,044
Research focus
Adverse EffectsCardiacHeartCardiovascular SystemExposure ToMedical DeviceAnimalsCardiac MyocytesMedicalPhthalatesToxic EffectTissuesAffectCellsNeonatalIn VivoOpticsCalciumNeonateBaseOperative Surgical ProceduresAdverse OutcomeArrhythmiaCardiovascular Diseases
Grant awards (18)
Does biocompatibility contribute to transfusion-related adverse effects?$878,124
R01 · FY2025 · HL · contact PI
Off-label drugs in cardiology: evaluating age- and disease-appropriate therapies$629,045
R01 · FY2025 · HD · contact PI
Off-label drugs in cardiology: evaluating age- and disease-appropriate therapies$652,993
R01 · FY2024 · HD · contact PI
Off-label drugs in cardiology: evaluating age- and disease-appropriate therapies$660,186
R01 · FY2023 · HD · contact PI
Off-label drugs in cardiology: evaluating age- and disease-appropriate therapies$685,049
R01 · FY2022 · HD · contact PI
Does Biocompatibility Contribute to Transfusion-Related Adverse Effects?$677,394
R01 · FY2022 · HL · contact PI
Does Biocompatibility Contribute to Transfusion-Related Adverse Effects?$677,394
R01 · FY2021 · HL · contact PI
Does Biocompatibility Contribute to Transfusion-Related Adverse Effects?$684,955
R01 · FY2020 · HL · contact PI
Does Biocompatibility Contribute to Transfusion-Related Adverse Effects?$684,312
R01 · FY2019 · HL · contact PI
Does Biocompatibility Contribute to Transfusion-Related Adverse Effects?$709,146
R01 · FY2018 · HL · contact PI
The effect of endocrine disrupting chemicals on cardiac physiology$242,704
R00 · FY2018 · ES · contact PI
The effect of endocrine disrupting chemicals on cardiac physiology$248,103
R00 · FY2017 · ES · contact PI
The effect of endocrine disrupting chemicals on cardiac physiology$249,000
R00 · FY2016 · ES · contact PI
The effect of endocrine disrupting chemicals on cardiac physiology$104,963
K99 · FY2015 · ES · contact PI
The effect of endocrine disrupting chemicals on cardiac physiology$104,963
K99 · FY2014 · ES · contact PI
The effect of phthalates on the heart: molecular pathways and clinical relevance$47,124
F32 · FY2013 · ES · contact PI
The effect of phthalates on the heart: molecular pathways and clinical relevance$52,190
F32 · FY2012 · ES · contact PI
The effect of phthalates on the heart: molecular pathways and clinical relevance$47,606
F32 · FY2010 · ES · contact PI